ReviewInternational journal of molecular sciences2026
3D Genome Engineering Using CRISPR/dCas Systems.
Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The spatial organization of the genome has emerged as a central regulator of gene expression and cellular function. Chromatin architecture is organized hierarchically across multiple spatial scales and involves chromatin loops, topologically associating domains (TADs), chromatin compartments, and specialized nuclear environments that collectively shape regulatory interactions within the nucleus. Disruption of these structures contributes to a wide range of diseases, including developmental disorders, cancer, and laminopathies, stimulating growing interest in technologies capable of programmable manipulation of genome topology. The emergence of CRISPR/dCas-based technologies has transformed the field from descriptive 3D genomics to programmable genome engineering. Catalytically inactive Cas proteins fused to architectural or epigenetic effectors enable targeted manipulation of chromatin loops, loop extrusion, subnuclear positioning, and local chromatin states without altering the underlying DNA sequence. In this review, we summarize current CRISPR/dCas-based approaches for engineering three-dimensional genome architecture, discuss their mechanistic basis and applications, and highlight emerging therapeutic opportunities and major technical challenges in the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.